The transaction creates the ninth-largest U.S. bank, fueling a new wave of consolidation in the regional banking sector.
The bank raised its price target to $220 from $160, citing 'sold out' high-bandwidth memory as a key catalyst for future growth.
The energy giant will use the proceeds to accelerate debt reduction and focus on its core oil and gas business.
Ascendiant Capital Markets reiterates a 'Buy' rating, citing significant undervaluation and projecting a potential 1,460% upside for the e-commerce firm.
FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
The fund, BGTF II, is now the world's largest private fund dedicated to clean energy and decarbonization, signaling strong investor confidence.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.